Teicoplanin Therapeutic Drug Monitoring and Treatment Outcomes in Children With Gram-Positive Infections

2021 ◽  
Author(s):  
Georgia Loane ◽  
Amanda Gwee
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Treatment Outcomes ◽  
Drug Monitoring ◽  
Drug Level ◽  
Therapeutic Drug ◽  
Gram Positive ◽  
Retrospective Audit ◽  
Trough Concentrations ◽  
Drug Level Monitoring ◽  
Level Monitoring

Abstract This is a retrospective audit of teicoplanin dosing, drug-level monitoring, and outcomes in 29 children who received 31 courses of teicoplanin. Our study of noncritically ill children showed that the majority (35/43, 81%) of trough concentrations were within the therapeutic range (10-30 mg/L) contrasting previous studies in children. Overall, 21 of the 24 (88%) children with Gram-positive infections achieved cure.

scholarly journals Therapeutic drug monitoring in epilepsy clinic: a multi-disciplinary approach

2014 ◽  
Vol 6 (4) ◽  
Author(s):  
Sunee Lertsinudom ◽  
Aporanee Chaiyakum ◽  
Supinya Tuntapakul ◽  
Kittisak Sawanyawisuth ◽  
Siriporn Tiamkao ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Public Health Problem ◽  
Clinical Information ◽  
Drug Level ◽  
Therapeutic Drug ◽  
Therapeutic Level ◽  
Drug Levels ◽  
Drug Level Monitoring ◽  
Level Monitoring

Epilepsy is a common public health problem and needs multi-disciplinary treatment. Therapeutic drug monitoring (TDM) is one of step of the multi-disciplinary treatment in epilepsy at Epilepsy clinic, Khon Kaen University (Thailand). The TDM service has been established since 2008. Here, we aimed to study the roles of TDM order and epilepsy control. This is a prospective descriptive study in which data collection was done from January 1 to December 31, 2010, the period when pharmacists took part in assessing the appropriateness in measurement and interpretation of TDM in order to provide suggestions for physicians. The 112 patients under study had an average age of 38.21±15.36 years; 254 samples were collected for therapeutic drug monitoring; phenytoin was submitted mostly for drug monitoring at 46.46%; 44.49% of sub-missions for drug level monitoring were made owing to a suspected sub-therapeutic level. Associations were found between reasons of sending samples for drug level monitoring and the measured drug levels, <em>i.e.</em>, 66.67% of drug levels found was so low that they were undetectable in sample for patients’ compliance investigation and 38.94% of the drug levels were found to be sub-therapeutic as for the case where submission of samples was done because of suspected sub-therapeutic level, 40% of the cases were found to be in toxicity range in the cases with suspected over-therapeutic levels and monitoring levels, 58.25% were found to be within the therapeutic range. Pharmacists used the interpreted results in patients’ care by recommending physicians to monitor therapeutic drug closely, to adjust the dosage of drugs, and to recommend checking patients’ compliance in their use of drugs at 56.5, 38.9, and 4.3%, respectively. Physicians’ responses were found to be absolute follow, partial follow and not follow at 77.95, 11.03, and 7.48%, respectively. In conclusion, associations were found between reasons of TDM order and measured drug level. Therapeutic drug monitoring services at the Epilepsy Clinic was useful in supporting clinical information queries. Pharmacists could make use of interpreted drug level information by recommending physicians to monitor drug levels and adjust individual dosage regimen accordingly. It should be noted that physicians accepted pharmacists’ recommendation, denoting multi-disciplinary care team that would lead to greater efficiency.

scholarly journals Cure of limb-threatening XDR Pseudomonas aeruginosa infection: combining genome sequencing, therapeutic drug level monitoring, and surgical debridement

2020 ◽  
Author(s):  
Shanti Narayanasamy ◽  
Roger L Nation ◽  
Andrew A Mahony ◽  
M Lindsay Grayson ◽  
Jason C Kwong ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Therapeutic Drug Monitoring ◽  
Drug Level ◽  
Surgical Debridement ◽  
Therapeutic Drug ◽  
Drug Resistant ◽  
Extensively Drug Resistant ◽  
Pseudomonas Aeruginosa Infection ◽  
Drug Level Monitoring ◽  
Level Monitoring

Abstract We describe a case of limb-threatening osteomyelitis and metalware infection with carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa successfully cured with aggressive surgical debridement and combined intravenous fosfomycin and colistin. Real-time therapeutic drug monitoring was used to maximize probability of efficacy and minimize potential for toxicity.

Drug level monitoring in palliative patients

2021 ◽  
pp. bmjspcare-2020-002613
Author(s):  
Joanne Bartlett ◽  
Elizabeth Freshwater
Keyword(s):  
Brain Tumour ◽  
Palliative Medicine ◽  
Drug Level ◽  
Therapeutic Drug ◽  
Primary Brain Tumour ◽  
Drug Level Monitoring ◽  
Symptoms And Signs ◽  
Level Monitoring ◽  
Palliative Patients

Palliative medicine is always patient centred and promotes the principle that no unnecessary investigations are performed. The case is reported of a patient with suspected carbamazepine toxicity presenting as progression of symptoms of primary brain tumour. A comparison is made of the symptoms and signs of toxicity versus tumour, and an aid for deciding when to perform therapeutic drug level monitoring for some common drugs.

Methotrexate Blood Level Monitoring

1985 ◽  
Vol 19 (5) ◽  
pp. 372-373 ◽  
Author(s):  
Helen St.C. Remington ◽  
Clifford C. Bailey
Keyword(s):  
Blood Level ◽  
Fluid Balance ◽  
Drug Level ◽  
Therapeutic Drug ◽  
High Dose ◽  
High Dose Therapy ◽  
Methotrexate Toxicity ◽  
Management Procedures ◽  
Drug Level Monitoring ◽  
Level Monitoring

Methotrexate toxicity can be avoided following high-dose therapy if certain management procedures are adhered to. These include careful fluid balance management and therapeutic drug level monitoring. A case is reported of an episode of methotrexate toxicity resulting from a fluid balance problem.

scholarly journals Therapeutic Drug Monitoring: Performance of a FRET-Based Point-Of-Care Immunoassay for the Quantitation of Infliximab and Adalimumab in Blood

2020 ◽  
Author(s):  
Edgar Ong ◽  
Ruo Huang ◽  
Richard Kirkland ◽  
Stefan Westin ◽  
Jared Salbato ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Whole Blood ◽  
Point Of Care ◽  
Resonance Energy Transfer ◽  
Resonance Energy ◽  
Drug Level ◽  
Analytical Performance ◽  
Quantitative Detection ◽  
Therapeutic Drug

<p>Two fast (<5 min), time-resolved fluorescence resonance energy transfer (FRET)-based immunoassays (Procise IFX™ and Procise ADL™) were developed for the quantitative detection of infliximab (IFX), adalimumab (ADL), and their respective biosimilars for use in therapeutic drug monitoring (TDM) using 20 µL of finger prick whole blood at the point-of-care or whole blood/serum in a central lab. Studies were performed to characterize analytical performance of the Procise IFX and the Procise ADL assays on the ProciseDx™ analyzer.</p> <p><br></p><p>The Procise IFX and Procise ADL assays both showed good analytical performance with respect to sensitivity, specificity, linearity, and precision suitable for routine clinical use as well as excellent correlation to current commercial ELISA IFX and ADL measurement methods.</p> <p><br></p><p>Results indicated that the Procise IFX and Procise ADL assays are sensitive, specific, and precise yielding results in less than 5 minutes from either whole blood or serum. This indicates the Procise IFX and Procise ADL assays are useful for obtaining fast and accurate IFX or ADL quantitation, thus avoiding delays inherent to current methods and enabling immediate drug level dosing decisions to be made during a single patient visit.</p>

scholarly journals Therapeutic Drug Monitoring: Fundamentals, And Optimization

2021 ◽  
Author(s):  
Ahmed Ali ◽  
Mahran Abdel-Rahman
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Cost Effective ◽  
Drug Level ◽  
Therapeutic Drug ◽  
Relevant Research ◽  
Request Form ◽  
Narrow Therapeutic Range ◽  
Analytical Tools

Therapeutic drug monitoring (TDM) is a teamwork clinical pharmacokinetic services aimed to optimize pharmacotherapy of certain drugs such as those with a narrow therapeutic range, complicated pharmacokinetics. It involves the determination of drug level in blood samples taken at the appropriate time. Interpretation of results requires integration of pharmacokinetics, the pharmacodynamics of the drug and the patient’s clinical profile. To be cost-effective the service should be optimized. This review was written by experts from different developing countries to highlight the fundamentals of the service and provide suggestions for its optimization. These cover the rationale of requesting drug level, design of request form, optimal sampling, and analytical tools. guidelines for appropriate interpretation of drug levels; completeness of the roles of the qualified medical team; continuing education and skills development; involve the patients in improving the service, conducting relevant research; use PK software and integration of TDM with pharmacogenomics

Sign in / Sign up

Export Citation Format

Share Document